Lawrence Panasci - Concepedia

Author

Lawrence Panasci

Also Known As

L C Panasci, L Panasci, L. C. Panasci, L. Panasci, L.C. Panasci, LAWRENCE CARL PANASCI, LAWRENCE PANASCI, Lawrence C Panasci, Lawrence C. Panasci, Lawrence Panasci

159

Publications

5.5K

Citations

H-Index

100

Concepts

All Affiliations

Jewish General Hospital McGill University

About

Lawrence Panasci is an author at Jewish General Hospital specializing in medicine, cell biology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	28	47	3K
2	Natural Sciences	8	8	374
3	Health Sciences	5	5	288
4	Engineering	1	1	72
5	Public Health	1	1	51

Lawrence Panasci

Publications

5.2K

Citations

H-Index

Page 1

	Year	Citations
Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. P Dombernowsky, I E Smith, Geoffrey Falkson, Journal of Clinical Oncology	1998	640
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial J.F.R. Robertson, Igor Bondarenko, Ekaterina Trishkina, The Lancet Mg VersusBreast OncologyOncologyEndocrine OncologyPharmacology	2016	580
Epstein‐barr virus related lymphoepithelioma‐like carcinoma of lung Louis R. Bégin, Jan Eskandari, J. H. Joncas, Journal of Surgical Oncology Epstein‐barr VirusLymphoid NeoplasiaUnusual HostEpstein-barr VirusMultiple Pulmonary Nodule	1987	241
Systemic cancer therapy: achievements and challenges that lie ahead Michael Palumbo, Petr Kavan, Wilson H. Miller, Frontiers in Pharmacology Systemic Cancer TherapyMedicineCancer ManagementNew Systemic TherapiesImmunology	2013	237
Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase Carolyn Algire, Lilian Amrein, Mahvash Zakikhani, Endocrine Related Cancer	2010	232
Small Molecules, Inhibitors of DNA-PK, Targeting DNA Repair, and Beyond David Davidson, Lilian Amrein, Lawrence Panasci, Frontiers in Pharmacology Dna DamageMolecular BiologyCancer BiologyTumor BiologyReceptor Tyrosine Kinase	2013	157
Pegylated Liposomal Doxorubicin and Trastuzumab in HER-2 Overexpressing Metastatic Breast Cancer: A Multicenter Phase II Trial Stephen Chia, Mark Clemons, L Abdel Kader Martin, Journal of Clinical Oncology	2006	138
Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot study Martine Puts, Johanne Monette, Véronique Girre, Critical Reviews in Oncology/Hematology Geriatric OncologyAgingGeriatricsLongevityMedicine	2010	123
Chemotherapy for advanced pancreatic cancer.A comparison of 5-fluorouracil, adriamycin, and mitomycin (fam) with 5-fluorouracil, streptozotocin, and mitomycin (fsm) Martin W. Oster, Robert J. Gray, Lawrence Panasci, Cancer Combination Chemotherapy ProgramsSurgical OncologyPancreatic CancerGastrointestinal OncologyMedicine	1986	122
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) Thomas Bachelot, Eva Ciruelos, Fabio Puglisi, Annals of Oncology Metastatic Breast CancerBreast OncologyMedicinePathologyPreliminary Safety	2019	111

Page 1